Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

IMA new masthead1

April 15, 2018

View Archives Issues

  • Elderly May Not Benefit From Statins for Primary Prevention

    In an examination of the data from the much-publicized Systolic Blood Pressure Intervention Trial (SPRINT), the author found no benefit of statin therapy for primary prevention of cardiovascular events or all-cause mortality.

  • Stroke Risk in Atrial Fibrillation: A Moving Target?

    An investigation of patients in a national database with atrial fibrillation, no comorbidities, and not on aspirin or anticoagulants showed that the clinical features that make up the CHA2DS2-VASc score change over time and can increase a patient’s risk for stroke, which could affect therapy decisions. Thus, the CHA2DS2-VASc score should be reassessed periodically and appropriate therapeutic actions taken promptly.

  • After Myocardial Infarction, Increased Risk for Ischemic Stroke Persists for 12 Weeks

    This study establishes that the elevated short-term risk of stroke extends beyond 30 days and remains elevated for up to 12 weeks following acute myocardial infarction.

  • Ibalizumab-uiyk Injection (Trogarzo)

    Ibalizumab-uiyk, in combination with other antiretrovirals, is indicated for the treatment of HIV-1 in heavily treatment-experienced adults with multidrug-resistant HIV infections failing their current regimens.

  • Clinical Briefs

    In this section: comparing GLP-1 agonists; weighing two treatments for extended venous thromboembolism; and considering fracture risks possibly associated with inhaled corticosteroids.

  • What Form of AV Block?

    The long lead II rhythm strip shown in the figure was obtained from a hemodynamically stable patient. The rhythm was diagnosed as showing second-degree AV block, Mobitz Type II. Do you agree with that assessment?